XERIS BIOPHARMA HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.76 USD | -6.38% |
|
-6.88% | -25.11% |
| May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
Presenter SpeechUnknown Analyst (Analysts)Welcome, everyone. Thank you for being here. I'm [in...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patientsâ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushingâs syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.
Sector
Pharmaceuticals
Calendar
2024-06-05
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.76
USD
Average target price
4.9
USD
Spread / Average Target
+178.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.11% | 261M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Transcript : Xeris Biopharma Holdings, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 12
